Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs ...

Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid ...

Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. Catalent says it worked on more than half of the new drugs approved by the FDA over the past 10 years.

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger ...